Tamoxifen
- PDF / 169,501 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 9 Downloads / 167 Views
1
S
Uterine polyp and uterine carcinoma: 2 case reports In a case-control study involving 80 post-menopausal women conducted between December 2018 and May 2019, 2 women were described, who developed uterine polyp or uterine carcinoma during treatment with tamoxifen for ER positive breast cancer. The women, who had diabetes and ER positive breast cancer, started receiving treatment with tamoxifen 20mg daily [routes not stated] along with metformin (1 woman) or with an unspecified hypoglycemic agent (1 woman). However, during the treatment, one woman (who received tamoxifen with metformin) developed uterine polyp, and the other woman (who received tamoxifen with an unspecified hypoglycemic agent) developed uterine carcinoma [durations of treatments to reactions onsets and outcomes not stated]. Author comment: "One of the most important side effects of postmenopausal tamoxifen treatment is its ability to increase a patient’s chance of developing endometrial lesions, including hyperplasia, polyps, carcinomas and sarcoma." Abd-Alhussain GK, et al. Inhibitory role of metformin for tamoxifen induced uterine cell proliferation in diabetic patients with er-positive breast cancer. International Journal of Research in Pharmaceutical Sciences 10: 2538-2541, No. 3, 2019. Available from: URL: http://doi.org/10.26452/ijrps.v10i3.1506 803443057 Iraq
0114-9954/20/1785-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved
Reactions 4 Jan 2020 No. 1785
Data Loading...
